Conference Proceedings
TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: A Phase I study
Funda Meric-Bernstam, Lipika Goyal, Tran Ben, Ignacio Matos, Hendrik-Tobias Arkenau, Helen He, Jerry Huang, Rastislav Bahleda
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2019
Abstract
Abstract Background TAS-120, an oral, highly selective, irreversible FGFR1-4 tyrosine kinase inhibitor, inhibits both mutant and wild-type FGFR1-4 isoforms and has demonstrated activity against cell lines and human xenografts of tumors bearing FGFR aberrations. Safety and antitumor activity of TAS-120 was evaluated in this phase 1 study (NCT02052778) in patients with advanced solid tumors. TAS-120 doses of 8-24 mg once daily continuously (QD) or 8-200 mg Monday-Wednesday-Friday were evaluated for safety in the dose-escalation phase. Continuous TAS-120 20 mg QD was determined to be the maximum tolerated dose (MTD). Results in patients with cholangiocarcinoma (CCA) bearing FG..
View full abstract